Skip to main content
SpringerLink
Log in

Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels

  • Reviews
  • Published:
International Journal of Clinical and Laboratory Research

Summary

Plasminogen activator inhibitor-1 plays a major role in the fibrinolytic system as the main physiological inhibitor of both tissue-type and urinary-type plasminogen activators. The inhibitor is present in plasma in small amounts and derives mainly from endothelial cells. Positive correlations have been reported between plasma levels and different parameters, such as serum triglycerides, insulin plasma levels and body mass index. Moreover, high plasma inhibitor concentrations have been observed in different disease states, but it must be stressed that plasminogen activator inhibitor-1 behaves as an acute-phase reactant and measurement of plasma levels is not significant in the acute phase of the disease. A possible predictive value of inhibitor levels for thrombotic events such as deep vein thrombosis and ischemic heart disease has been studied. On the basis of available studies, the predictive value is not clear for venous thrombosis, whereas plasminogen activator inhibitor-1 levels can predict some coronary events, at least in subgroups of young patients with a first myocardial infarction. It remains to be established if treatments able to reduce plasma inhibitor levels lead to a decrease in the risk of thromboembolic events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague I, Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 55:30, 1986

    Google Scholar 

  2. Andreotti F, Roncaglioni MC, Hackett DR, Khan MI, Regan S, Haider AW, Davies GJ, Kluft C, Maseri A, Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. J Am Coll Cardiol 16:1553, 1990

    Article  PubMed  CAS  Google Scholar 

  3. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Har Zahav Y, Modan M, Zivelin A, Laniado S, Seligsohn U, Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 64:1231, 1989

    Article  PubMed  CAS  Google Scholar 

  4. Booth NA, Anderson JA, Bennett B, Platelet release protein which inhibits plasminogen activators. J Clin Pathol 38:825, 1985

    PubMed  CAS  Google Scholar 

  5. Booth NA, Simpson AJ, Croli A, Bennett B, MacGregor IR, Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70:327, 1988

    PubMed  CAS  Google Scholar 

  6. Cambien F, Jacoveson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR, Is the level of serum triglycerides a significant predictor of coronary death in normocholesterolemic subjects? Am J Epidemiol 126:86, 1987

    Google Scholar 

  7. Carlsson LA, Aberg H, Serum triglycerides—an independent risk factor for myocardial infarction but not for angina pectoris. N Engl J Med 312:1127, 1985

    Google Scholar 

  8. Declerck PJ, Alessi MC, Verstreken MV, Kruithof EKO, Juhan-Vague I, Collen D, Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71:220, 1988

    PubMed  CAS  Google Scholar 

  9. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D, Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454, 1988

    PubMed  CAS  Google Scholar 

  10. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO, A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 77:528, 1991

    PubMed  Google Scholar 

  11. Dosne AM, Dupuy E, Bodevin E, Partial characterization of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 12:377, 1978

    Article  PubMed  CAS  Google Scholar 

  12. Engesser L, Brommer EJP, Kluft C, Briet E, Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 62:672, 1989

    Google Scholar 

  13. Erickson LA, Ginsberg MH, Loskutoff DJ, Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 74:1465, 1984

    PubMed  CAS  Google Scholar 

  14. Estellés A, Aznar J, Tormo G, Sapena P, Tormo V, Espana F, Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction. Thromb Res 55:203, 1989

    Article  PubMed  Google Scholar 

  15. Grimaudo V, Bachmann F, Havert V, Christe MA, Kruithof EKO, Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost 67:397, 1992

    PubMed  CAS  Google Scholar 

  16. Haire WD, Goldsmith JC, Rasmussen J, Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activators inhibitors. Am J Hematol 31:36, 1988

    Article  Google Scholar 

  17. Hamsten A, Wiman B, Faire U de, Blomback M, Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557, 1985

    Article  PubMed  CAS  Google Scholar 

  18. Hamsten A, Faire U de, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet II:3, 1987

    Article  Google Scholar 

  19. Hekman CM, Loskutoff DJ, Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581, 1985

    PubMed  CAS  Google Scholar 

  20. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR, A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 67:209, 1992

    PubMed  CAS  Google Scholar 

  21. Jorgensen M, Bonnevie-Nielsen V, Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 65:175, 1987

    PubMed  CAS  Google Scholar 

  22. Juhan-Vague I, Moerman B, Cock F de, Aillaud MF, Collen D, Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33:523, 1984

    Article  PubMed  CAS  Google Scholar 

  23. Juhan-Vague I, Aillaud MF, Cock F de, Philip-Joet C, Arnaud C, Seradimigni A, Collen D, The fast-acting inhibitor of tissue-type plasminogen activator in an acute phase reactant protein. In: Davidson JF, Donati MB, Coccheri S (eds) Progress in fibrinolysis. Churchill Livingstone, London, p 146, 1985

    Google Scholar 

  24. Juhan-Vague I, Alessi MC, Fossat C, Valadier J, Aillaud MF, Serradimigni A, Clinical relevance of reduced t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 57:67, 1987

    PubMed  CAS  Google Scholar 

  25. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Ailaud MF, Atlan C, Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 13:331, 1987

    PubMed  CAS  Google Scholar 

  26. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, Serradimigni A, Collen D, Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 9:362, 1989

    PubMed  CAS  Google Scholar 

  27. Juhan-Vague I, Alessi MC, Raccali D, Aillaud MF, Billerey M, Ansaldi J, Philip-Joet C, Vague P, Daytime fluctuation of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 67:76, 1992

    PubMed  CAS  Google Scholar 

  28. Kluft C, Jie AFH, Sprengers ED, Verheijen JH, Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett 190:315, 1985

    Article  PubMed  CAS  Google Scholar 

  29. Kruithof EKO, Gudinchet A, Bachmann F, Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 59:7, 1988

    PubMed  CAS  Google Scholar 

  30. Laug WE, Vascular smooth muscle cells inhibit plasminogen activators secreted by endothelial cells. Thromb Haemost 20:165, 1985

    Google Scholar 

  31. Legnani C, Maccaferri M, Tonini P, Cassio A, Cacciari E, Coccheri S, Reduced fibrinolytic response in obese children: association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 2:211, 1988

    Article  Google Scholar 

  32. Levi M, Lensing AWA, Buller HR, Prandoni P, Dooijewaard G, Cuppini S, Cate JW ten, Deep vein thrombosis and fibrinolysis: defective urokinase type plasminogen activator release. Thromb Haemost 66:426, 1991

    PubMed  CAS  Google Scholar 

  33. MacGregor IR, Booth NA, An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1). Thromb Haemost 59:68, 1988

    PubMed  CAS  Google Scholar 

  34. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ 1:153, 1979

    Article  PubMed  CAS  Google Scholar 

  35. Mehta J, Mehta P, Lawson D, Saldeen T, Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentration. J Am Coll Cardiol 9:263, 1987

    Article  PubMed  CAS  Google Scholar 

  36. Munkvad S, Jespersen J, Gram J, Kluft C, Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium. J Int Med Res 228:361, 1990

    Article  CAS  Google Scholar 

  37. Potter Van Loon BJ, Rijken DC, Brommer EJP, Van Der Maas APC, The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the reaction to ex-vivo lysibility. Thromb Haemost 67:101, 1992

    PubMed  CAS  Google Scholar 

  38. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G, Identification and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 74:1989, 1990

    Google Scholar 

  39. Prins MH, Hirsh J, A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 151:1721, 1991

    Article  PubMed  CAS  Google Scholar 

  40. Ranby M, Sundell IB, Nilsson TK, Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62:917, 1989

    PubMed  CAS  Google Scholar 

  41. Simpson AJ, Booth NA, Moore NR, Bennett B, The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 75:543, 1990

    PubMed  CAS  Google Scholar 

  42. Simpson AJ, Booth NA, Moore NR, Bennett B, Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 44:139, 1991

    PubMed  CAS  Google Scholar 

  43. Sprengers ED, A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma. Thromb Haemost 55:74, 1986

    PubMed  CAS  Google Scholar 

  44. Sprengers ED, Kluft C, Plasminogen activator inhibitors. Blood 69:381, 1987

    PubMed  CAS  Google Scholar 

  45. Sprengers ED, Princen HMG, Kooistra T, Van Hinsbergh VWM, Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 105:751, 1985

    PubMed  CAS  Google Scholar 

  46. Sprengers ED, Akkerman JWN, Jansen BG, Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 55:325, 1986

    PubMed  CAS  Google Scholar 

  47. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn Se, Larson VG, Cain KC, Beard JC, Abrass IB, Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 83:1692, 1991

    PubMed  CAS  Google Scholar 

  48. Takada Y, Takada A, Measurement of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator activator in human plasma. Thromb Res Suppl 8:15, 1988

    Article  PubMed  CAS  Google Scholar 

  49. Urano T, Sumiyoshi K, Nakamura M, Mori T, Takada Y, Takada, A, Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female. Thromb Res 60:133, 1990

    Article  PubMed  CAS  Google Scholar 

  50. Urdén G, Hamsten A, Wiman B, Comparison of plasminogen activator inhibitor activity and antigen in plasma samples. Clin Chim Acta 169:189, 1987

    Article  PubMed  Google Scholar 

  51. Wagner OF, Vries C de, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tisue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 84:647, 1989

    Article  PubMed  CAS  Google Scholar 

  52. Wiman B, Hamsten A, Abnormal fibrinolysis as an etiologic factor in thromboembolic disease (abstract). Thromb Haemost 62:13, 1989

    Google Scholar 

  53. Zalewski A, Shi Y, Nardone D, Bravette B, Weinstock P, Fischman D, Wilson P, Goldberg S, Levin DC, Bjornsson TD, Evidence for reduced fibrinolytic activity in unstable angina at rest: clinical, biochemical, and angiographic correlates. Circulation 83:1685, 1991

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Medica I, Viale Morgagni 85, I-50134, Firenze, Italy

    Domenico Prisco, Elena Chiarantini, Maria Boddi, Carlo Rostagno, Andrea Colella & Gian Franco Gensini

Authors
  1. Domenico Prisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Chiarantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Boddi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo Rostagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Colella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gian Franco Gensini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prisco, D., Chiarantini, E., Boddi, M. et al. Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels. Int J Clin Lab Res 23, 78–82 (1993). https://doi.org/10.1007/BF02592287

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02592287

Key words

Search

Navigation